Open AccessMonitoring the safety of antiretroviral drugs in patients with HIV infection
Author(s) -
А. В. Матвеев,
А. Е. Крашенинников,
Е. А. Егорова,
Е. И. Коняева
Publication year - 2021
Publication title -
vič-infekciâ i immunosupressii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.176
H-Index - 4
eISSN - 2078-1792
pISSN - 2077-9828
DOI - 10.22328/2077-9828-2021-13-1-115-123
Subject(s) - efavirenz , zidovudine , lamivudine , medicine , nevirapine , adverse effect , antiretroviral therapy , reverse transcriptase inhibitor , human immunodeficiency virus (hiv) , antiretroviral drug , incidence (geometry) , nucleoside reverse transcriptase inhibitor , drug , pharmacotherapy , adverse drug reaction , drug reaction , pharmacology , viral load , virology , viral disease , virus , hepatitis b virus , physics , optics
The antiretroviral therapy is a lifelong use of a combination of three or more antiretroviral drugs (ARVDs). One of the factors contributing to a significant decrease in patients’ adherence to treatment is the high toxicity of ARVs. The aim of the study is to study the safety of antiretroviral drugs retrospectively and based on spontaneous reports about adverse drug reactions (ADRs) inputted in the ARCADe database. Materials and method. The objects of our research were the 649 spontaneous messages about ARVDs recorded in the regional electronic database (register) of spontaneous messages for period 01 January 2009 — 31 December 2018. Results. Most often, ADR were registered with the use of combined ARVD and non-nucleoside reverse transcriptase inhibitors. Zidovudine and Efavirenz were the leaders in terms of the incidence of ARV ADR. Among the combined anti-HIV drugs, the most frequently ADR were associated with the use of a Lamivudine and Zidovudine combination. Conclusion. Long-term use of ARVs requires regular monitoring of adverse reactions, which will improve the quality of life of patients with HIV infection and significantly increase their compliance with antiretroviral pharmacotherapy.